Open | - |
Close | - |
Volume / Avg. | 32.000 / 1.465M |
Day Range | - - - |
52 Wk Range | 1.080 - 5.000 |
Market Cap | $167.038M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 48 |
Short Interest | 6.43% |
Days to Cover | 1.47 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of G1 Therapeutics (NASDAQ: GTHX) through any online brokerage.
Other companies in G1 Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Innate Pharma (NASDAQ:IPHA), Graphite Bio (NASDAQ:GRPH), Atossa Therapeutics (NASDAQ:ATOS) and GlycoMimetics (NASDAQ:GLYC).
The latest price target for G1 Therapeutics (NASDAQ: GTHX) was reported by Needham on Wednesday, February 28, 2024. The analyst firm set a price target for 12.00 expecting GTHX to rise to within 12 months (a possible 275.00% upside). 17 analyst firms have reported ratings in the last year.
The stock price for G1 Therapeutics (NASDAQ: GTHX) is $3.2 last updated March 15, 2024 at 7:43 AM EDT.
There are no upcoming dividends for G1 Therapeutics.
G1 Therapeutics’s Q1 earnings are confirmed for Wednesday, May 1, 2024.
There is no upcoming split for G1 Therapeutics.
G1 Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.